RANI
What one share of Rani Therapeutics Holdings holds
Pharmaceutical Preparations
We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections.
Rani Therapeutics Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.04 |
|---|---|
| Profit | −$0.22 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.15 |
| Cash and investments | $0.03 |
| Debt | $0.00 |
| Book value | $0.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.14 | −$0.43 | $0.03 | −$1.68 | — | $2.43 |
| 2022 | $0.00 | −$1.28 | $0.07 | −$2.02 | — | $1.55 |
| 2023 | $0.00 | −$1.33 | $0.05 | −$2.06 | — | $0.50 |
| 2024 | $0.04 | −$1.05 | $0.01 | −$1.26 | — | $0.07 |
| 2025 | $0.02 | −$0.45 | $0.00 | −$0.28 | — | $0.50 |